Showing results (351-360 of 366) with videos related to

Sort By:
Pageof 37
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2024
SARS-CoV-2-specific CD8+ T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 yearsLouise C Rowntree, Jennifer Audsley, Lilith F Allen, et al.
Cell Reports. Medicine|February 10, 2021
Integrated immune dynamics define correlates of COVID-19 severity and antibody responsesMarios Koutsakos, Louise C Rowntree, Luca Hensen, et al.
JCI Insight|April 10, 2023
Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbationsJennifer R Habel, Brendon Y Chua, Lukasz Kedzierski, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 2, 2025
HLA-B*15:01-positive severe COVID-19 patients lack CD8+ T cell pools with highly expanded public clonotypesLouise C Rowntree, Lilith F Allen, Ruth R Hagen, et al.
The New England Journal of Medicine|February 25, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, Anthony C Gordon, Paul R Mouncey, et al.
JAMA|March 22, 2022
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial, Charlotte A Bradbury, Patrick R Lawler, et al.
Thorax|May 13, 2025
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Anthony C Gordon, Paul R Mouncey, et al.
The New England Journal of Medicine|October 27, 2023
Simvastatin in Critically Ill Patients with Covid-19, Thomas E Hills, Elizabeth Lorenzi, et al.
Critical Care Medicine|May 8, 2026
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)Madiha Hashmi, Rashan Haniffa, Deva Jayakumar, et al.
Journal of Thrombosis and Haemostasis : JTH|March 27, 2026
Intermediate Dose Heparin Thromboprophylaxis among Critically Ill Patients with COVID-19: A Randomised Clinical Trial, Charlotte A Bradbury, Bryan J McVerry, et al.
Pageof 37